23,057 Shares in FibroBiologics, Inc. (NASDAQ:FBLG) Bought by Rhumbline Advisers

Rhumbline Advisers acquired a new stake in FibroBiologics, Inc. (NASDAQ:FBLG) in the 2nd quarter, HoldingsChannel.com reports. The firm acquired 23,057 shares of the company’s stock, valued at approximately $115,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Cascade Financial Partners LLC bought a new stake in shares of FibroBiologics during the 2nd quarter worth $1,572,000. ERn Financial LLC bought a new stake in FibroBiologics in the second quarter worth about $159,000. Bank of New York Mellon Corp bought a new stake in FibroBiologics in the second quarter worth about $342,000. Concurrent Investment Advisors LLC purchased a new position in FibroBiologics in the second quarter valued at about $176,000. Finally, Saxon Interests Inc. bought a new position in shares of FibroBiologics during the 2nd quarter valued at approximately $106,000.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on FBLG shares. Maxim Group started coverage on FibroBiologics in a research note on Tuesday, September 24th. They issued a “buy” rating and a $12.00 price objective on the stock. EF Hutton Acquisition Co. I upgraded FibroBiologics to a “strong-buy” rating in a research note on Wednesday, September 4th.

FibroBiologics Price Performance

Shares of FibroBiologics stock opened at $3.09 on Tuesday. The company’s 50-day moving average price is $2.89 and its 200-day moving average price is $6.81. FibroBiologics, Inc. has a 12-month low of $1.08 and a 12-month high of $55.00.

FibroBiologics (NASDAQ:FBLG) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). Equities analysts forecast that FibroBiologics, Inc. will post -0.37 earnings per share for the current year.

FibroBiologics Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.